Testing a Potential Therapeutic Target for Lymphoma
A cure for canine lymphoma remains elusive, in part because of the lack of molecular-targeted therapies that can circumvent chemotherapy resistance. The research team’s previous findings suggest that valosin-containing protein (VCP) holds particular promise as a therapeutic target. In this study, they will test a known inhibitor of VCP to see if this results in preferential killing of lymphoma cells over healthy cells and to determine the critical mechanisms through which the anticancer effect is achieved. Identifying new therapeutic targets for canine lymphoma is the first step toward developing better treatments for this deadly disease.
Principal Investigator: Dr. Marie-Eve Nadeau, University of Montreal, Canada, First Award Grant
Study ID: D14CA-324